Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Scios
Scios
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Natrecor
Nesiritide
2001-08-10
Paroxysmal dyspnea
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Nesiritide
heart transplantation
,
acute kidney injury
,
left ventricular dysfunction
,
diastolic heart failure
,
paroxysmal dyspnea
,
cardiopulmonary bypass
,
coronary disease
,
myocardial ischemia
,
coronary artery bypass
,
myocardial infarction
,
systolic heart failure
,
acute coronary syndrome
,
kidney diseases
,
heart failure
,
renal insufficiency
,
cardiomyopathies
,
dyspnea
,
pulmonary edema
,
aneurysm
,
hypertension
,
dilated cardiomyopathy
Enoblituzumab
cystic fibrosis
Caficrestat
heart failure
,
renal insufficiency
,
cardiomyopathies
,
paroxysmal dyspnea
Bevifimod
healthy volunteers/patients
,
psoriasis
,
postmenopausal osteoporosis
TALMAPIMOD
rheumatoid arthritis
,
arthritis
,
multiple myeloma
,
plasma cell neoplasms
,
myelodysplastic syndromes
,
hematologic diseases
,
preleukemia
,
bone marrow diseases
,
syndrome
,
bone marrow neoplasms
Antineoplaston a10
healthy volunteers/patients
,
malnutrition
,
pain
,
allergic rhinitis perennial
Hidroxicloroquina
cutaneous lupus erythematosus
,
rheumatoid arthritis
,
arthritis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use